The implications of hyponitroxia in cancer

Translational Oncology

Volumn 7, Issue 2, 2014, Pages 167-173

  Oronsky, Bryan ^a   Fanger, Gary R ^a   Oronsky, Neil ^b   Knox, Susan ^c   Scicinski, Jan ^a  

^a RadioRx Inc   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c CFLS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; N (G) NITROARGININE; NAVELBINE; NITRIC OXIDE; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RRX 001; THROMBOSPONDIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOTOXICITY; DNA METHYLATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; HISTONE MODIFICATION; HORMESIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; MITOGENICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84902515220     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.02.001     Document Type: Review

References (63)

1. Moncada S, Palmer RM, and Higgs EA (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43, 109-142.
2. Oronsky BT, Knox SJ, and Scicinski JJ (2012). Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review. Transl Oncol 5, 66-71.
3. Ambs S and Glynn SA (2011). Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle 10, 619-624.
4. Andrew PJ and Mayer B (1999). Enzymatic function of nitric oxide synthases. Cardiovasc Res 43, 521-531.
5. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, and Wink DA (2005). Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A 102, 13147-13152.
6. Fukumura D, Kashiwagi S, and Jain RK (2006). The role of nitric oxide in tumour progression. Nat Rev Cancer 6, 521-534.
7. Klotz T, Bloch W, Volberg C, Engelmann U, and Addicks K (1998). Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82, 1897-1903.
8. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M, and Ando M (1997). Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 88, 1190-1198.
9. Lala PK (1998). Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy. Cancer Metastasis Rev 17, 1-6.
10. Calabrese EJ (2010). Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 29, 249-261.
11. Brüne B and Zhou J (2003). The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1α (HIF-1α). Curr Med Chem 10, 845-855.
12. Berchner-Pfannschmidt U, Yamac H, Trinidad B, and Fandrey J (2007). Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J Biol Chem 282, 1788-1796.
13. Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, and Saenz de Tejada I (1993). Oxygen tension regulates the nitric oxide pathway: physiological role in penile erection. J Clin Invest 91, 437-442.
14. Matthews NE, Adams MA, Maxwell LR, Gofton TE, and Graham CH (2001). Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 93, 1879-1885.
15. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, and Waldman SA (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52, 375-414.
16. Brüne B (2003). Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 10, 864-869.
17. Prieto CP, Krause BJ, Quezada C, San Martin R, Sobrevia L, and Casanello P (2011). Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium. Placenta 32, 932-940.
18. Brantley EC, Guo L, Zhang C, Lin Q, Yokoi K, Langley RR, Kruzel E, Maya M, Kim SW, and Kim SJ, et al (2010). Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol 3, 380-388.
19. Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, and Rocha S (2010). Mechanism of hypoxia-induced NF-κB. Mol Cell Biol 30, 4901-4921.
20. Jordan BF, Sonveaux P, Feron O, Grégoire V, Beghein N, Dessy C, and Gallez B (2004). Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer 109, 768-773.
21. Oronsky BT, Scicinski JJ, Reid T, and Knox S (2012). Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review. Transl Oncol 5, 133-140.
22. Mocellin S, Bronte V, and Nitti D (2007). Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 27, 317-352.
23. Squadrito GL and Pryor WA (1998). Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med 25, 392-403.
24. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, and Fidler IJ (1995). Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181, 1333-1343.
25. Casaril M, Corso F, Bassi A, Capra F, Gabrielli GB, Stanzial AM, Nicoli N, and Corrocher R (1994). Decreased activity of scavenger enzymes in human hepatocellular carcinoma, but not in liver metastases. Int J Clin Lab Res 24, 94-97.
26. Fiaschi T and Chiarugi P (2012). Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol 2012, 762825.
27. Barrera G (2012). Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012, 137289.
28. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, Sessa WC, Gerweck LE, Jain RK, and Fukumura D (2008). Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 14, 255-257.
29. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, and Sessa WC (1998). Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101, 731-736.
30. Nott A and Riccio A (2009). Nitric oxide-mediated epigenetic mechanisms in developing neurons. Cell Cycle 8, 725-730.
31. Hickok JR, Vasudevan D, Antholine WE, and Thomas DD (2013). Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. J Biol Chem 288, 16004-16015.
32. Illi B, Colussi C, Grasselli A, Farsetti A, Capogrossi MC, and Gaetano C (2009). NO sparks off chromatin: tales of a multifaceted epigenetic regulator. Pharmacol Ther 123, 344-352.
33. Matouk CC and Marsden PA (2008). Epigenetic regulation of vascular endothelial gene expression. Circ Res 102, 873-887.
34. Pienta KJ, McGregor N, Axelrod R, and Axelrod DE (2008). Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 1, 158-164.
35. Hmadcha A, Bedoya FJ, Sobrino F, and Pintado E (1999). Methylation-dependent gene silencing induced by interleukin 1β via nitric oxide production. J Exp Med 190, 1595-1604.
36. Wu RC and Schönthal AH (1997). Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem 272, 29091-29098.
37. te Poele RH, Okorokov AL, Jardine L, Cummings J, and Joel SP (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62, 1876-1883.
38. Ewald JA, Desotelle JA, Wilding G, and Jarrard DF (2010). Therapy-induced senescence in cancer. J Natl Cancer Inst 102, 1536-1546.
39. Ibiza S and Serrador J (2008). The role of nitric oxide in the regulation of adaptive immune responses. Inmunologia 27, 103-117.
40. Lee SW, Choi H, Eun SY, Fukuyama S, and Croft M (2011). Nitric oxide modulates TGF-β-directive signals to suppress Foxp3+ regulatory T cell differentiation and potentiate Th1 development. J Immunol 186, 6972-6980.
41. Bingisser RM, Tilbrook PA, Holt PG, and Kees UR (1998). Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160, 5729-5734.
42. Marshall HE and Stamler JS (2002). Nitrosative stress-induced apoptosis through inhibition of NF-κB. J Biol Chem 277, 34223-34228.
43. Lander HM, Ogiste JS, Teng KK, and Novogrodsky A (1995). p21ras as a common signaling target of reactive free radicals and cellular redox stress. J Biol Chem 270, 21195-21198.
44. Boscá L, Zeini M, Través PG, and Hortelano S (2005). Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. Toxicology 208, 249-258.
45. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, and Schmitt E, et al (2007). Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5, e38.
46. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, and Bromberg JS (2009). Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182, 259-273.
47. Sonkoly E, Ståhle M, and Pivarcsi A (2008). MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 18, 131-140.
48. Garbán HJ and Bonavida B (2001). Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 167, 75-81.
49. Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, and Bonavida B (2009). Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 20, 39-52.
50. Ignarro LJ, Napoli C, and Loscalzo J (2002). Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90, 21-28.
51. Sonveaux P, Frérart F, Bouzin C, Brouet A, Dewever J, Jordan BF, Gallez B, and Feron O (2007). Irradiation promotes Akt-targeting therapeutic gene delivery to the tumor vasculature. Int J Radiat Oncol Biol Phys 67, 1155-1162.
52. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, and Okazaki T, et al (2006). Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 24, 688-694.
53. Xu W, Liu LZ, Loizidou M, Ahmed M, and Charles IG (2002). The role of nitric oxide in cancer. Cell Res 12, 311-320.
54. Cardnell RJ and Mikkelsen RB (2011). Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One 6, e20147.
55. Schulze A and Harris AL (2012). How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364-373.
56. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, and Hoskin PJ (2007). Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8, 111-118.
57. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, and Knox SJ (2012). Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res 72, 2600-2608.
58. Fens M, Larkin S, Morris C, Fitch B, Scicinski J, Oronsky B, and Kuypers F (2011). NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. Blood (ASH Annual Meeting Abstracts) 118, 2125.
59. Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, and Fitch WL (2012). Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos 40, 1810-1816.
60. Tritto I and Ambrosio G (2004). The multi-faceted behavior of nitric oxide in vascular "inflammation": catchy terminology or true phenomenon? Cardiovasc Res 63, 1-4.
61. Calabrese EJ (2001). Nitric oxide: biphasic dose responses. Crit Rev Toxicol 31, 489-501.
62. Oronsky BT, Knox SJ, and Scicinski J (2011). Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol 4, 189-198.
63. Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, and Scicinski J (2013). Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm. Theranostics 3, 437-447.